ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28082400.
- Also identified by DOI 10.1158/0008-5472.CAN-16-2621 and PMC identifier 5313321.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Muscle-invasive bladder cancer (MIBC) generally responds poorly to treatment and tends to exhibit significant mortality. Here we show that expression of the tumor suppressor p14<sup>ARF</sup> (ARF) is upregulated in aggressive subtypes of MIBC. Accumulation of ARF in the nucleolus is associated with poor outcome and attenuated response to chemotherapy. In both genetically engineered mouse models and murine xenograft models of human MIBC, we demonstrate that tumors expressing ARF failed to respond to treatment with the platinum-based chemotherapy agent cisplatin. Resistance was mediated in part by the integrin-binding protein <i>ITGB3BP</i> (<i>CENPR</i>) and reflected ARF-dependent impairment of protein translation, which was exaggerated by drug treatment. Overall, our results highlight a context-dependent role for ARF in modulating the drug response of bladder cancer. <i>Cancer Res; 77(4); 1035-46. ©2017 AACR</i>.
Medical subject headings
- Tumor Suppressor Protein p14ARF
- Urinary Bladder Neoplasms